<?xml version="1.0" encoding="UTF-8"?>
<p>IAPP is released together with insulin in response to metabolic stimuli, supporting a role for IAPP in glucose metabolism, possibly as an insulin counter-regulatory hormone
 <xref rid="CIT0018" ref-type="bibr">
  <sup>18</sup>
 </xref>. Post-mortem, IAPP amyloid is present in 96% of individuals with T2D
 <xref rid="CIT0019" ref-type="bibr">
  <sup>19</sup>
 </xref>, and recently detected in pancreas biopsies from patients newly diagnosed with Type 1 diabetes (T1D)
 <xref rid="CIT0020" ref-type="bibr">
  <sup>20</sup>
 </xref>. Oligomers that occur early in the amyloidogenesis are cytotoxic to Î²-cells
 <xref rid="CIT0021" ref-type="bibr">
  <sup>21</sup>
 </xref>
 <sup>,</sup>
 <xref rid="CIT0022" ref-type="bibr">
  <sup>22</sup>
 </xref>, and the amyloid deposits disrupt islet architecture and interfere with cell-cell signalling. For this reason, more anti-diabetic drugs with complementary mechanisms of action should be developed.
</p>
